
MBX Stock Forecast & Price Target
MBX Analyst Ratings
Bulls say
MBX Biosciences is a biopharmaceutical company with a strong pipeline and promising early data for their lead asset, canvuparatide, in the treatment of hypoparathyroidism. With a differentiated platform and novel treatment approach, the company shows potential for significant upside in the market. Despite initial market reaction to early data, analysts remain bullish on the potential of MBX 4291 and canvuparatide, projecting peak sales in the billions.
Bears say
MBX Biosciences is at a critical stage with one product in Phase 1 trials and another in Phase 2 trials, with a high risk of failure and low likelihood of profitability in the near future. Additionally, the company's product candidates face strong competition, and their efficacy and safety profiles are not significantly better than existing therapies in the same class. The company's current valuation is largely speculative, and its long-term success is uncertain.
This aggregate rating is based on analysts' research of MBX Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
MBX Analyst Forecast & Price Prediction
Start investing in MBX
Order type
Buy in
Order amount
Est. shares
0 shares